Yes, tirzepatide is FDA approved. It’s sold under two brand names for three distinct uses: Mounjaro for type 2 diabetes, and Zepbound for chronic weight management and obstructive sleep apnea. All three approvals came between May 2022 and late 2024, making tirzepatide one of the most rapidly expanded drug approvals in recent years.
Approved Uses and Brand Names
Tirzepatide first received FDA approval as Mounjaro, intended for adults with type 2 diabetes alongside diet and exercise. The same active ingredient was then approved under the brand name Zepbound on November 8, 2023, for chronic weight management in adults who meet specific criteria. Most recently, the FDA approved Zepbound as the first medication for moderate to severe obstructive sleep apnea in adults with obesity.
For weight management, you need either a BMI of 30 or higher (obesity) or a BMI of 27 or higher (overweight) with at least one weight-related condition. Qualifying conditions include high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. In both cases, the prescription is meant to accompany a reduced-calorie diet and increased physical activity.
The sleep apnea approval was based on two year-long studies involving 469 adults without type 2 diabetes. After 52 weeks, participants on tirzepatide experienced significantly fewer breathing interruptions per hour during sleep compared to placebo. Greater proportions of treated patients achieved remission or mild sleep apnea with resolution of symptoms.
How Tirzepatide Works
Tirzepatide targets two hormone receptors at once, which is what sets it apart from older medications in the same class. It activates both the GIP receptor and the GLP-1 receptor. Most people are familiar with GLP-1 drugs like semaglutide (Ozempic, Wegovy). Tirzepatide adds GIP activation on top of that.
Both of these hormones are released naturally by your gut after eating. GLP-1 slows stomach emptying, promotes feelings of fullness, and stimulates insulin release when blood sugar is elevated. GIP also boosts insulin production and has effects in fat tissue, bone, and the brain. When both hormones work together, the insulin response and blood sugar control are stronger than either one alone. The combined appetite-suppressing effect is what drives the significant weight loss seen in clinical trials.
Dosing and How It’s Taken
Tirzepatide is a once-weekly injection given just under the skin, typically in the abdomen, thigh, or upper arm. Everyone starts at the lowest dose of 2.5 mg per week for the first four weeks. This starting period isn’t really a treatment dose; it’s designed to let your body adjust and reduce the chance of digestive side effects.
After four weeks, the dose increases to 5 mg weekly. From there, your doctor may increase it in 2.5 mg steps, waiting at least four weeks between each increase, up to a maximum of 15 mg per week. Each monthly supply comes as a box of four prefilled pens.
Side Effects and Safety Warnings
The most common side effects are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. These are reported in at least 5% of patients and tend to be worst during dose increases. The gradual titration schedule exists specifically to minimize these effects, and for most people they ease over time.
Tirzepatide carries an FDA boxed warning, the most serious type of safety notice, regarding thyroid tumors. In rat studies, the drug caused thyroid C-cell tumors at doses comparable to what humans receive. Whether this translates to a risk in people remains unknown. Because of this uncertainty, tirzepatide is not prescribed to anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you notice a lump in your neck, difficulty swallowing, trouble breathing, or persistent hoarseness while taking tirzepatide, those warrant prompt medical attention.
Cost and Insurance Coverage
The list price for Mounjaro is $1,112.16 per monthly supply (four pens). Zepbound is priced similarly. What you actually pay depends heavily on your insurance plan’s formulary and your pharmacy benefit structure.
Eli Lilly offers a savings card program for commercially insured patients that can substantially reduce out-of-pocket costs. However, patients covered by Medicare, Medicaid, TRICARE, VA, or other government programs are not eligible for the savings card. If you don’t have commercial insurance, Lilly’s patient support line (1-800-545-5979) can provide information on other affordability options.
Coverage varies widely. Many commercial insurers now cover tirzepatide for type 2 diabetes, but coverage for weight management remains inconsistent. Some plans exclude weight loss medications entirely, while others require prior authorization or documented failure of other treatments before approving it.